| P50 | author | Takeshi Terashima | Q89626161 |
| P2093 | author name string | Tatsuya Yamashita | |
| | Eishiro Mizukoshi | |
| | Taro Yamashita | |
| | Shuichi Kaneko | |
| | Masao Honda | |
| | Yoshio Sakai | |
| | Hidetoshi Nakagawa | |
| | Kuniaki Arai | |
| | Kazuya Kitamura | |
| | Noriho Iida | |
| | Takashi Kagaya | |
| P2860 | cites work | Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis | Q27022482 |
| | Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 |
| | Cancer-related inflammation | Q27860907 |
| | Immunity, Inflammation, and Cancer | Q27861048 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Management of hepatocellular carcinoma | Q29616230 |
| | Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib | Q33411190 |
| | When progressive disease does not mean treatment failure: reconsidering the criteria for progression | Q37003248 |
| | Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma | Q37235531 |
| | Diagnosis of hepatocellular carcinoma: newer radiological tools | Q38030775 |
| | An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. | Q39850331 |
| | Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma | Q42977612 |
| | A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). | Q43880241 |
| | Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update | Q44079528 |
| | Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization | Q44165064 |
| | Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment | Q44934585 |
| | Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation | Q45358708 |
| | Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. | Q50909590 |
| | Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. | Q53491592 |
| | Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers | Q56985475 |
| | A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation | Q57762889 |
| P921 | main subject | chemotherapy | Q974135 |
| | hepatocellular carcinoma | Q1148337 |
| P577 | publication date | 2014-10-16 | |
| P1433 | published in | Hepatology Research | Q15752035 |
| P1476 | title | Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy | |